問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 110Taipei CitySin Yi

Recruiting Trial

221Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

439Cases

2020-11-19 - 2024-12-31

Phase III

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

  • Condition/Disease

    Chronic Kidney Disease With Metabolic Acidosis

  • Test Drug

    TRC101

Participate Sites
12Sites

Recruiting11Sites

Terminated1Sites

2016-12-15 - 2019-12-31

Phase II

Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects with Moderate to Severe Rheumatoid Arthritis

  • Condition/Disease

    類風濕性關節炎

  • Test Drug

    GS-5745

Participate Sites
7Sites

Terminated6Sites

2016-12-01 - 2021-12-31

Phase III

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

  • Condition/Disease

    Rheumatoid arthritis

  • Test Drug

    Filgotinib

Participate Sites
12Sites

Terminated11Sites

方耀凡
Linkou Chang Gung Medical Foundation

藍忠亮
China Medical University Hospital-Taipei

未分科

2019-11-13 - 2021-03-18

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Filgotinib

Participate Sites
6Sites

Terminated6Sites

2020-02-27 - 2024-01-31

Phase III

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    (1) Filgotinib; (2) Adalimumab

Participate Sites
13Sites

Terminated13Sites

2012-02-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-07-07 - 2012-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-09-01 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-01-01 - 2020-02-29

Phase III

A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influenza Complications

  • Condition/Disease

    Influenza

  • Test Drug

    S-033188

Participate Sites
11Sites

Terminated11Sites

2018-06-29 - 2022-06-30

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BMS-986165

Participate Sites
8Sites

Recruiting8Sites

張棋楨
Taipei Medical University Hospital

1 35 36 37 38 39 44
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB